IXICO PLC

("IXICO" or the "Company")

Issue of Equity

IXICO plc (AIM: IXI), a global leader in neuroscience imaging and biomarker analytics, using its AI-driven platform to help advance drug development in neurological disorders, announces that further to the 'Placings and Subscription' announcement dated 31 March 2026, the Company is pleased to confirm that it has now received Advance Assurance from HM Revenue & Customs under the Income Tax Act 2007. Consequently, all conditions relating to the First Placing and Subscription have been satisfied.

Director Shareholdings

The following Directors subscribed for New Ordinary Shares pursuant to the Fundraising. The number of new Ordinary Shares subscribed for by each Director and their resulting shareholdings upon Admission are set out below:

(1)  The number of Ordinary Shares presented in this table as being held or subscribed for by Directors refers to the number of Ordinary Shares held or subscribed for by them either personally or through a nominee.

The notifications below, made in accordance with the requirements of the UK Market Abuse Regulation, provide further details.

Admission and Total Voting Rights

Application has been made for the New Ordinary Shares to be admitted to trading on AIM. It is expected that First Admission will become effective at 8.00 a.m. on 24 April 2026 and Second Admission will become effective at 8.00 a.m. on 27 April 2026.

Following First Admission and Second Admission, the total number of Ordinary Shares in the capital of the Company in issue will be 218,047,596 with each Ordinary Share carrying the right to one vote. There are no shares held in treasury and therefore, following Fist Admission and Second Admission, the total number of voting rights in the Company will be 218,047,596.

The above figure may be used by Shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure, Guidance and Transparency Rules.

Capitalised terms used in this announcement have the meaning given to them in the announcement dated 31 March 2026, unless otherwise defined in this announcement.

Enquiries:

 About IXICO www.IXICO.com

IXICO is a global leader in neuroscience imaging and biomarker analytics, using its proprietary AI-driven platform to help advance the treatment of neurological disorders and reduce the uncertainties associated with drug discovery, development and monitoring.  As a key part of the global neurological disease research community, the Company has built a global reputation and 20-year track record as an end-to-end Imaging Contract Research Organisation (iCRO) working with leading pharma companies, innovative biotechs, disease consortia and non-profit organisations. IXICO has supported hundreds of neurological clinical trials, analysed hundreds of thousands scans and built an expansive network of expert imaging centres around the world. 

The IXI^TM Platform is tailor-made for neurological disease, reliably processing data from global trials, precisely measuring key imaging biomarkers associated with the identification, progression and treatment of diseases such as Alzheimer's, Huntington's and Parkinson's.  Image data is interrogated by the Platform and IXICO's expert scientists translating complex data into clinically meaningful while minimizing data variability and increasing reproducibility.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.